Swati Gupta

EGFR Targeted Gemcitabine PLGA Nanoparticles for Pancreatic Cancer

Buch

Adenocarcinoma of the exocrine pancreas is the fourth leading cause of cancer deaths in the United States. Currently, surgery is the only treatment, although due to its late presentation, only 9% to 15% of patients are suitable for surgery. The median survival for all stages of pancreatic cancer is 3 to 5 months from diagnosis. The underlying problem in the use of anticancer drugs is their toxicity and poor bioavailability. It is expected that if a delivery system-bearing anticancer drugs can be delivered in a targeted fashion, inhibition of tumor growth with reduced systemic toxicity will occur. The book describes the preparation and charact… Mehr

CHF 82.00

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen

V105: Folgt in ca. 15 Arbeitstagen

Produktdetails

Weitere Autoren: Aggarwal, Sahil

ISBN: 978-3-659-76831-6
EAN: 9783659768316
Produktnummer: 37404793
Verlag: LAP Lambert Academic Publishing
Sprache: Englisch
Erscheinungsjahr: 2015
Seitenangabe: 140 S.
Masse: H22.0 cm x B15.0 cm x D0.8 cm 227 g
Abbildungen: Paperback
Gewicht: 227

Über den Autor

Swati Gupta (M.Pharm, Ph.D), has nearly thirteen years of research experience. She has supervised 15 M.Pharm students and supervising Ph.D students. Dr Gupta has been awarded with BOYSCAST fellowship and Bio-CARe women scientist award from Ministry of Science and Technology, New Delhi. Dr Gupta has over forty five publications to her credit.